Xcout Intel
Phlox Therapeutics
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
Subscribe to see Phlox Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Phlox Therapeutics at a glance
Phlox Therapeutics is a biotechnology company headquartered in Netherlands. Its most recent funding round, Seed, closed in May 2022. Xcout tracks 5 named people at Phlox Therapeutics, including Margien Boels (Director of Operations).
Phlox Therapeutics leadership
- Margien BoelsDirector of Operations
- Eva van RooijCSO (founder)
- Yigal PintoCMO (founder)
- Rianne EllenbroekNon-executive Director
- Ross GordonObserver
Phlox Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Phlox Therapeutics competitors
A few of Phlox Therapeutics's closest competitors — see the full list of competitors and alternatives →
Cardior Pharmaceuticals GmbH is a clinical-stage biopharmaceutical company headquartered in Hannover, Germany. Established in 2016, the company focuses on discovering and developing RNA-based therapeutics for the prevention and treatment of heart diseases.
Nuevocor is a biotechnology research company with its headquarters located in Singapore and additional operations in the United States and France. The company focuses on developing breakthrough gene therapies to treat untreatable cardiomyopathies.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
River BioMedics is a Dutch biotechnology company headquartered in Enschede, Netherlands, founded in 2018. The company focuses on cardiovascular drug discovery by utilizing proprietary 3D human engineered heart tissue models to address unmet medical needs.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
XyloCor Therapeutics is a clinical-stage biopharmaceutical company headquartered in King of Prussia, Pennsylvania, focused on developing novel gene therapies for advanced coronary artery disease. The company is dedicated to improving patient outcomes through innovative cardiovascular treatments.
Get Phlox Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Phlox Therapeutics in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access